Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Mar 21, 2024 2:27pm

59 Views

Post# 35945528

RE:RE:RE:RE:New Press Release - Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

It's a bit ackward but that's just Thera. They are like the rainman of PRs. It's possible we get some signs in the next part3 leg of P1. After that it depends on the cash on hand or lack of. The P1 data should be available q1 2025 and that,s when you could expect a deal if results are good. Before that it could just be a Katana version of the past like someone said here.

<< Previous

Bullboard Posts

Next >>

Nevada gold stock scores multiple high-grade hits